Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.

Abstract	We report the efficacy and safety of intravenous low-dose alemtuzumab (10 mg three times weekly for 10 weeks) in 12 patients with relapsed or refractory chronic lymphocytic leukemia. Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression.
Authors	Luca Laurenti, Paola Piccioni, Michela Tarnani, Dimitar G Efremov, Alessia Fiorini, Mariagrazia Garzia, Simona Sica
Journal	Haematologica (Haematologica) Vol. 90 Issue 8 Pg. 1143-5 (Aug 2005) ISSN: 1592-8721 [Electronic] Italy
PMID	16079121 (Publication Type: Letter)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Neoplasm Antineoplastic Agents Alemtuzumab
Topics	Aged Alemtuzumab Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Humanized Antibodies, Neoplasm (therapeutic use) Antineoplastic Agents (therapeutic use) Female Humans Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy) Lymphocyte Count Male Middle Aged Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!